GlassScriptPhysician profile
Michelle A Homan
NPI 1780995720
$8,366.58
in general payments reported to CMS, 2019-2025
16 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $14.92 · 2021: $78.59 · 2022: $7,409 · 2023: $558 · 2024: $67.95 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $203 · Food and Beverage: $199 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $92.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $202.50 |
| Food and Beverage | $198.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $92.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,626.54 | 2022-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.00 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| La Jolla Pharmaceutical Company | $132.32 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $74.75 | 2023 | Acthar |
| Genzyme Corporation | $71.58 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $62.44 | 2019-2024 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $51.21 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Inogen, INC. | $36.60 | 2022-2024 | |
| Grifols USA, LLC | $33.18 | 2021-2022 | |
| Amgen INC. | $27.81 | 2022-2023 | Tezspire |
| Abbvie INC. | $19.39 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.63 | 2021 | |
| Circassia INC. | $17.76 | 2019 | |
| Genentech USA, INC. | $17.57 | 2023 | Xolair |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Homan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.